Technology · Health & biomedicine / Regenerative & personalized medicine

FemTech biotech & women's health

Specialized biologic, diagnostic and live-biotherapeutic products for conditions that affect exclusively or disproportionately women — non-invasive endometriosis testing, ovarian-longevity therapeutics, vaginal-microbiome LBPs and cfDNA prenatal screening, under FDA, EU IVDR/EMA and NMPA oversight.

Risk: medium Pharma & biologics US · EU · CN verified 2026-06-28 · 6 Sources (0 independent)

1 · What it gives

FemTech biotech develops biologics, drugs and diagnostics for conditions that affect exclusively or disproportionately women, targeting a medical gender gap where endometriosis alone affects roughly 10% of reproductive-age women yet historically took 7–10 years to diagnose through invasive laparoscopy. The 2026 frontier concentrates on four directions: non-invasive endometriosis diagnostics from saliva miRNA (Ziwig Endotest, fast-track reimbursed for 25,000 patients across 80 French medical centres since February 2025, reading 109 miRNA markers with reported above-95% diagnostic accuracy in the ENDOmiRNA study); ovarian-longevity and fertility therapeutics that slow ovarian ageing to extend the natural fertility window and defer menopause; vaginal-microbiome live biotherapeutic products (LBPs) built on Lactobacillus crispatus consortia to restore an acidic vaginal pH below 4.5 and prevent bacterial vaginosis and preterm birth; and next-generation non-invasive prenatal testing (NIPT) that sequences cell-free fetal DNA (cfDNA) from maternal blood, where BGI’s NIFTY has analysed more than 10 million pregnancies. The stack is regulated end-to-end — FDA drugs and devices in the US, the EU In Vitro Diagnostic Regulation (IVDR 2017/746) Class C for miRNA tests plus EMA for therapeutics in Europe, and NMPA registration in China.

The key directions of FemTech biotech & women’s health are:

Non-invasive endometriosis diagnostics: saliva miRNA sequencing and menstrual-blood liquid biopsy (Ziwig Endotest, NextGen Jane Smart Tampon) that replace diagnostic laparoscopy with a mail-in lab test returning a staged diagnosis in days.
Ovarian-longevity and fertility therapeutics: target discovery and non-hormonal drug design (Celmatix Resolve platform, now partnered with Gedeon Richter) to slow ovarian ageing, protect the follicle pool during chemotherapy, and defer menopause.
Vaginal-microbiome live biotherapeutics: L. crispatus consortia formulated as lyophilized vaginal LBPs (Novonesis/Lactobio) to restore a healthy acidic microbiome and reduce bacterial-vaginosis and preterm-birth risk.
Non-invasive prenatal testing (NIPT): high-throughput cfDNA sequencing of fetal DNA in maternal blood (BGI NIFTY) to screen for fetal chromosomal aneuploidies early in pregnancy.

Sectoral value chain#

[Sample sourcing] ──> [Omics profiling] ──> [AI biomarker decoding]
      │                     │                       │
(saliva, menstrual,     (RNA-seq, cfDNA)    (miRNA → disease score)
 venous blood kits)                                   │
                                                       ▼
[Clinical delivery] <─── [GMP formulation] <─── [Therapeutic R&D]
(reimbursement, CE-IVD)     (LBP, peptide)     (ovarian, microbiome)

Value chain levels#

Level	Description	Key inputs/outputs
Sample sourcing	Painless at-home or clinic collection kits for saliva (RNA-stabilizing buffer), menstrual blood (smart tampons) or venous blood.	In: Patient biofluid, RNA-stabilizing tubes. Out: Stabilized nucleic-acid sample.
Omics profiling	Total and small-RNA extraction, small-RNA library preparation and next-generation sequencing (NGS) of miRNA or cfDNA.	In: Stabilized sample, RNA-seq reagents. Out: FASTQ files of small RNA / cfDNA reads.
AI signature	Machine-learning models (SVM, CNN, random forest) that turn the miRNA expression matrix into a disease probability and stage.	In: RNA-seq data, validated biomarker panel. Out: Disease probability index and stage.
Ovarian R&D	Target discovery for slowing ovarian ageing, and design of non-hormonal peptides and hormonal modulators (e.g. AMH agonists).	In: Oocyte cultures, AI target models. Out: Clinical candidates for ovarian longevity.
LBP microecology	Selection of L. crispatus strains and formulation of stable cryoprotected lyophilized vaginal suppositories or capsules.	In: Lactobacillus strains, GMP fermenters, cryoprotectants. Out: Drug-form vaginal LBP.
Clinical delivery	CE-IVD / FDA licensing of the diagnostic, reimbursement negotiation with insurers, and Rx market access for therapeutics.	In: Clinical-trial data, IVD dossier. Out: Reimbursed, clinically accessible FemTech tests and drugs.

Cross-cutting technologies of the sector:

Saliva miRNA liquid biopsy: high-sensitivity profiling of non-coding microRNAs carried in salivary exosomes; a 109-miRNA panel reports endometriosis with diagnostic accuracy above 95%, replacing invasive laparoscopy with a mail-in test.
L. crispatus live biotherapeutics: vaginal LBPs built on L-microbe-producing L. crispatus strains that hold vaginal pH below 4.5, blocking colonization by pathogenic anaerobes and cutting the risk of ascending reproductive infections and preterm birth.
Anti-Müllerian hormone (AMH) engineering: recombinant AMH molecules and receptor agonists that temporarily place the ovary in a dormant state during chemotherapy or to control ovarian reserve, preserving female fertility.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

1
Saliva collection and transport
The patient spits into a Ziwig Endotest tube; on cap-rotation a stabilizing buffer of chaotropic salts and RNase inhibitors is released, instantly denaturing salivary proteins and preserving exosomal extracellular RNA, and the tube is mailed to the central accredited laboratory.
2
Automated total and small-RNA extractionExtractionEquipment & engineering
A robotic liquid handler (e.g. Hamilton Microlab) transfers stabilized saliva to an extraction plate; isopropanol and silica magnetic beads bind RNA in chaotropic salt, three alcohol washes remove salts, proteins and mucins, and RNA is eluted in RNase-free water with quality checked on an Agilent Bioanalyzer for a crisp small-RNA peak.
Who can do this step matched automatically
Angel Yeast 安琪酵母 (SSE 600298) China
✓ GMP 228,000 tons
“It produces bread/Chinese-staple yeasts, yeast extracts, brewing yeasts, yeast protein and other food ingredients, animal feed additives, and nutrition/health products, leveraging …”
China Everbright Environment Group China
163,050 tonnes
“[China Everbright Environment Group Limited — China Everbright Environment Group is a leading integrated environmental protection conglomerate with diversified core businesses in …”
Algal Bio Japan
industrial scale
“EPC support”
3
Small-RNA library preparationFormulation & blending
A T4 RNA ligase attaches a 3’ and then a 5’ single-stranded RNA adapter to the small-RNA fraction; reverse transcription synthesizes cDNA, and 15 cycles of PCR with unique TruSeq index primers barcode each patient’s library.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ GMP 500 m3
“This is a satellite blending, mixing and formulation facility, located at Vashind near Shahapur and dedicated to the company’s Animal Nutrition business.”
SyAqua Group Thailand
“vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”
Taiwan Sugar Corporation (TSC) Taiwan
500,000 tons pilot scale
“It refines sugar (including refined white sugar, golden brown sugar, fine granulated sugar and invert sugar syrup), produces bio-based chemicals/biotech outputs (alcohol, …”
Rossari Biotech (NSE) India
industrial scale
“The company also announced a new greenfield blending facility in Thailand to boost Southeast Asia operations and smarter capacity utilization across its HPPC, TSC, and AHN …”
4
Precision size selection
The PCR product is loaded onto a preparative gel-electrophoresis system (e.g. Pippin Prep); a built-in laser detects DNA fragments migrating through agarose, and at 140–160 bp the instrument switches current to collect the clean miRNA-library fraction while discarding adapter dimers at about 120 bp.
5
NGS sequencingTesting & analytics
Purified libraries are quantified by qPCR, up to 96 patient libraries are pooled equimolarly, denatured, and loaded on an Illumina NextSeq 550 flow cell for single-end 50 bp sequencing at a depth of at least 5 million reads per sample.
Who can do this step matched automatically
Bloomage Biotechnology China
✓ GMP 320 tons industrial scale
“The company positions MitoEGT® as a mitochondria-targeting anti-aging ingredient with multiple efficacy studies, 38 patents, national metrology recognition, and plans to broaden …”
Esco Aster Singapore
5,000 L industrial scale
“Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
Vaxxinova Norway Norway
industrial scale
“Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.”
Turion Labs Singapore
“Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
6
AI signature and clinical reportData, software & automation
Reads are demultiplexed, adapter-trimmed, quality-filtered and aligned to the miRBase small-RNA database and the hg38 reference; a count matrix of the 109-miRNA panel is fed to a trained SVM model that outputs endometriosis probability, stage and phenotype; a clinical geneticist verifies the report and returns it to the gynaecologist, often sparing the patient a diagnostic laparoscopy.
Who can do this step matched automatically
China Everbright Environment Group China
163,050 tonnes
“As the fundamental component of 5G deployment, optic fibre is critical to making Hong Kong a smart city and laying the groundwork for IoT.”
Geo Biogás & Carbon Brazil
industrial scale
“The Artificial intelligence is clearly a female <<”
Sanatech Seed Japan
industrial scale
“Its business spans seed development, agricultural data platforms (soil, water quality, crop data), and partnerships with farmers and feed companies, with aspirations to integrate …”

4 · Who delivers

Matched suppliers (matched automatically)

Novonesis	Denmark	Producer	active
HLB Genex (ex-GenoFocus)	South Korea	Producer	active
Tsingke Biotechnology	China	Producer	active
Hipra	Spain	Producer	active
Codexis	United States	Producer	active

Leading companies and institutes (from the brief)

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Ziwig	🇫🇷 France	Endotest (salivary endometriosis test)	Saliva 109-miRNA panel + AI decoder; FR reimbursement 25k patients / 80 centres	operating
BGI Genomics	🇨🇳 China	NIFTY cfDNA prenatal test	High-throughput fetal cfDNA NGS; >10M pregnancies; NMPA priority review	commercial
Organon	🇺🇸 USA	Jada System, Nexplanon	Dedicated women’s-health pharma; $6.2B 2025 revenue; NYSE: OGN	commercial
Celmatix	🇺🇸 USA	Resolve ovarian platform	AI ovarian-reserve mapping; non-hormonal candidates; portfolio → Gedeon Richter	operating
Novonesis	🇩🇰 Denmark	L. crispatus vaginal LBP	Multi-strain synbiotic; VIBRANT Phase 1; ML strain selection	commercial
NextGen Jane	🇺🇸 USA	Smart Tampon platform	Menstrual DNA/RNA/microbiome liquid biopsy; 2nd NIH SBIR grant May 2025	operating

5 · Rules & route to market

United States

The United States holds the deepest FemTech venture base and the largest dedicated women’s-health pharma, commercializing ovarian-longevity therapeutics and molecular tampons while NIH grants de-risk early diagnostics.

Ovarian-longevity R&D, molecular tampon, dedicated FemTech pharma, NIH funding#

Celmatix and ovarian longevity: Celmatix’s Resolve platform uses multi-omic and clinical big data to map ovarian reserve and design non-hormonal candidates against ovarian ageing, and Hungarian pharma Gedeon Richter has acquired Celmatix’s women’s-health drug-discovery portfolio spanning fertility and endometriosis programs.
NextGen Jane (Smart Tampon): NextGen Jane turns an ordinary tampon into a liquid-biopsy device, isolating endometrial cells and extracellular RNA from menstrual blood for non-invasive endometriosis and fibroid diagnosis; it validated a DNA/RNA/microbiome menstrual system in 2025 and received its second NIH SBIR Direct-to-Phase-II grant in May 2025.
Organon (NYSE: OGN): spun out of MSD/Merck in 2021, Organon is the largest dedicated women’s-health company, reporting $6.2 billion in full-year 2025 revenue and $1.91 billion adjusted EBITDA (30.7% margin), with the postpartum-haemorrhage Jada System and the Nexplanon contraceptive implant.

European Union

The European Union is the global regulatory and technological pioneer of non-invasive endometriosis liquid biopsy, pairing the breakthrough Ziwig salivary test with strict IVDR Class C oversight and a live-biotherapeutic pipeline from Novonesis.

Ziwig Endotest (France), Novonesis/Lactobio (Denmark), CE-IVDR Class C#

Ziwig Endotest: the French biotech Ziwig built the first salivary endometriosis test, sequencing 109 salivary miRNA markers and decoding them with AI; France granted fast-track reimbursement for 25,000 patients across 80 medical centres in February 2025, and the ENDOmiRNA study — the largest saliva-biomarker study worldwide — confirmed its accuracy in December 2025.
Novonesis (ex-Lactobio), Denmark: Novonesis (which absorbed the Lactobio team via Chr. Hansen) runs a multi-strain L. crispatus vaginal synbiotic programme, with a randomized placebo-controlled trial (NCT05659745) and the VIBRANT Phase 1 trial of L. crispatus live biotherapeutics for bacterial vaginosis, using machine learning to predict probiotic function from vaginal strains.
IVDR Class C: European regulators classify early miRNA diagnostics under the IVDR 2017/746 as Class C, requiring exhaustive multi-centre validation studies and independent notified-body audit before CE marking — the bar Ziwig cleared for its reimbursement.

China

China develops FemTech under explicit state policy to support fertility and cut maternal and infant mortality, with BGI Genomics running the world’s largest non-invasive prenatal testing programme and CAS institutes researching premature ovarian insufficiency.

NIPT leadership (BGI Genomics), CAS reproductive institutes, vaginal probiotics#

BGI Genomics (NIFTY): BGI Genomics’ NIFTY cfDNA test has analysed more than 10 million pregnancies worldwide, screening fetal trisomies (including Down syndrome) from maternal-blood cfDNA, and the upgraded NIFTY version has entered NMPA priority review.
CAS reproductive institutes: the Shanghai institutes of the Chinese Academy of Sciences coordinate research into premature ovarian insufficiency (POI) and early menopause, and Chinese clinics run trials of collagen-scaffold mesenchymal-stem-cell therapy to regenerate the endometrium after injury.
Vaginal-probiotic production: Chinese manufacturers produce large volumes of reproductive-health probiotics and are writing vaginal-microecology standards into national gynaecology guidelines.

6 · Money: tenders & grants

Grant	Health of ecosystems and wild species, predictions and impacts on human health, in the face of existing and … European Commission · EU	Sep 22, 2027 341 days
Grant	Microbiome for terrestrial livestock sustainability and health within a One Health approach European Commission · EU	Sep 23, 2027 342 days
Grant	Advancing Global Health Bureau of Global Health Security and Diplomacy · United States	Feb 14, 2027 121 days
Grant	DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural … Defense Health Agency Contracting Activity - DHACA · United States	Sep 30, 2027 349 days
Grant	Enhancing ecodesign and circularity of construction products European Commission · EU	Sep 22, 2027 341 days

7 · Tech stack & innovations

The FemTech biotech stack joins a small-RNA/cfDNA sequencing core, an AI biomarker-decoding layer, and a live-biotherapeutic formulation layer.

Small-RNA (miRNA) extraction and NGS library preparation:
- Silica magnetic nanoparticles with tuned porosity capture the delicate 19–24-nucleotide miRNA fraction while washing away ribosomal and genomic RNA, and a Pippin-Prep-style preparative gel electrophoresis size-selects the 140–160 bp miRNA-plus-adapter library, stripping PCR adapter-dimer contamination.
AI miRNA-signature decoding:
- A trained machine-learning model (SVM / random forest) takes the normalized expression of the 109-miRNA endometriosis panel and outputs a disease probability, stage and phenotype, turning a saliva sample into a clinical diagnosis without laparoscopy.
Lyophilized L. crispatus live biotherapeutics:
- L. crispatus biomass is freeze-dried with protectant sugars (trehalose, sorbitol) on a temperature profile that prevents acid damage to cell walls, holding a stable titre above 1 billion CFU per suppository for ambient storage.

Sources 6 · 0 independent · 6 producer sites

Producers' own sites 6

Ziwig producer checked 2025-12-02 · link not kept
Bgi producer checked 2026-06-28 · link not kept
Organon producer checked 2026-02-12 · link not kept
Celmatix producer checked 2026-03-04 · link not kept
Novonesis producer checked 2026-04-01 · link not kept
Nextgen jane producer checked 2026-05-05 · link not kept